ACROBiosystems/ActiveMax® Human IFN-gamma / IFNG Protein, Tag Free/100ug/IFG

价格
¥18580.00
货号:IFG
浏览量:127
品牌:ACROBiosystems
服务
全国联保
正品保证
正规发票
签订合同
商品描述
  • Synonym
    Interferon-gamma ,Interferon-γ
  • Source
    ActiveMax® Human IFN-gamma, Tag Free (IFG-H4211) is expressed from human 293 cells (HEK293). It contains AA Gln 24 - Gln 166 (Accession # AAH70256).
    Predicted N-terminus: Gln 24
    Request for sequence
  • Molecular Characterization
    Online(Gln 24 - Gln 166) AAH70256

    This protein carries no "tag".

    The protein has a calculated MW of 16.8 kDa. The protein migrates as 19-25 kDa under reducing (R) condition (SDS-PAGE) due to differentglycosylation.

  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >90% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
ActiveMax® Human IFN-gamma, Tag Free (Cat. No. IFG-H4211) SDS-PAGE gel

ActiveMax® Human IFN-gamma, Tag Free on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.

Bioactivity-ELISA
ActiveMax® Human IFN-gamma, Tag FreeActiveMax® Human IFN-gamma, Tag Free (Cat. No. IFG-H4211) ELISA bioactivity

Immobilized ActiveMax® Human IFN-gamma, Tag Free (Cat. No. IFG-H4211) at 5 μg/mL (100 μL/well) can bind Human IFN-gamma R1, Fc Tag (Cat. No. IF1-H5254) with a linear range of 1-10 ng/mL (QC tested).

Protocol
Bioactivity-Cell based assay
Human FcRn Heterodimer Protein Cell_Base

The bio-activity of ActiveMax® Human IFN-gamma, Tag Free (Cat. No. IFG-H4211) was determined by dose-dependent inhibition of the proliferation of HT-29 cells. The EC50 for this effect is typically 0.41-0.74 ng/mL (Routinely tested).

Protocol
  • Citations
    • Diffusion of cytokines in live lymph node tissue using microfluidic integrated optical imaging

      Authors: A.E. Ross, et al.

      Journal: ANAL CHIM ACTA 2017

      Application:

      Request for Full-text

    • Improved therapeutic efficacy of mammalian expressed-recombinant interferon gamma against ovarian cancer cells

      Authors: Razaghi A, et al.

      Journal: Exp Cell Res 2017

      Application: Cell Culture

      Request for Full-text

  • Background
    Interferon-gamma (IFN-γ/IFNG) is a dimerized soluble cytokine that is the only member of the type II class of interferon. This interferon was originally called macrophage-activating factor, a term now used to describe a larger family of proteins to which IFN-γ belongs. IFN-gamma has been used in a wide variety of clinical indications. Interferon-gamma (IFNgamma) is a central regulator of the immune response and signals via the Janus Activated Kinase (JAK)-Signal Transducer and Activator of Transcription (STAT) pathway. Interferon gamma has broader roles in activation of innate and adaptive immune responses to viruses and tumors, in part through upregulating transcription of genes involved in cell cycle regulation, apoptosis, and antigen processing/presentation. Despite this, rodent and human trophoblast cells show dampened responses to IFNG that reflect the resistance of these cells to IFNG-mediated activation of major histocompatibility complex (MHC) class II transplantation antigen expression.
  • References
    • (1)Gray PW, et al., 1982, Nature 298 (5877): 859–63.
    • (2)Miller CH, et al., 2009, Ann N Y Acad Sci.1182:69-79.
    • (3)Saha B, et al., 2010, Cytokine. 50(1):1-14.
    • (4)Murphy SP, et al., 2009, Biol Reprod. 80(5):848-59.
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

ACROBiosystems治疗性抗体的功效不仅取决于Fab片段及其与靶抗原的结合活性,还取决于Fc片段及其与关键Fc受体的相互作用。Fc片段对FcRn的结合亲和力(FCGRT&B2M)将预测抗体的半衰期,而Fc片段与FcγRIIIa(CD16a)之间的结合亲和力将影响抗体引发ADCC的能力(抗体依赖性细胞介导的细胞毒性)。因此,必须在抗体工程化过程中针对一组受体测试候选人。ACROBiosystems提供了完整的重组Fc受体蛋白集合,包括它们的常见变体,以帮助您加快mAb的开发。